338 related articles for article (PubMed ID: 30549299)
21. Potential of human γδ T cells for immunotherapy of osteosarcoma.
Li Z
Mol Biol Rep; 2013 Jan; 40(1):427-37. PubMed ID: 23065272
[TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
23. Promise and Challenges of T Cell Immunotherapy for Osteosarcoma.
Park JA; Cheung NV
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569894
[TBL] [Abstract][Full Text] [Related]
24. Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma.
Dumars C; Ngyuen JM; Gaultier A; Lanel R; Corradini N; Gouin F; Heymann D; Heymann MF
Oncotarget; 2016 Nov; 7(48):78343-78354. PubMed ID: 27823976
[TBL] [Abstract][Full Text] [Related]
25. IL-11Rα: a novel target for the treatment of osteosarcoma.
Lewis VO
Adv Exp Med Biol; 2014; 804():285-9. PubMed ID: 24924180
[TBL] [Abstract][Full Text] [Related]
26. Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect.
Kiany S; Gordon N
Methods Mol Biol; 2016; 1441():285-95. PubMed ID: 27177675
[TBL] [Abstract][Full Text] [Related]
27. Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.
Ratti C; Botti L; Cancila V; Galvan S; Torselli I; Garofalo C; Manara MC; Bongiovanni L; Valenti CF; Burocchi A; Parenza M; Cappetti B; Sangaletti S; Tripodo C; Scotlandi K; Colombo MP; Chiodoni C
Clin Cancer Res; 2017 Sep; 23(17):5149-5161. PubMed ID: 28600479
[No Abstract] [Full Text] [Related]
28. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract][Full Text] [Related]
29. Surface expression of the immunotherapeutic target G
Wiebel M; Kailayangiri S; Altvater B; Meltzer J; Grobe K; Kupich S; Rossig C
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1394. PubMed ID: 33811471
[TBL] [Abstract][Full Text] [Related]
30. Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma.
Yang Q; Hu J; Jia Z; Wang Q; Wang J; Dao LH; Zhang W; Zhang S; Xia X; Gorlick R; Li S
Clin Cancer Res; 2022 Sep; 28(17):3862-3873. PubMed ID: 35727602
[TBL] [Abstract][Full Text] [Related]
31. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
[No Abstract] [Full Text] [Related]
32. Glycan Structures in Osteosarcoma as Targets for Lectin-Based Chimeric Antigen Receptor Immunotherapy.
Prasse N; Wessolowski C; Müller I; Cornils K; Franke AK
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791381
[TBL] [Abstract][Full Text] [Related]
33. Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.
Rosewell Shaw A; Porter CE; Watanabe N; Tanoue K; Sikora A; Gottschalk S; Brenner MK; Suzuki M
Mol Ther; 2017 Nov; 25(11):2440-2451. PubMed ID: 28974431
[TBL] [Abstract][Full Text] [Related]
34. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
35. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
36. Primary Bone Tumors: Challenges and Opportunities for CAR-T Therapies.
Folkert IW; Devalaraja S; Linette GP; Weber K; Haldar M
J Bone Miner Res; 2019 Oct; 34(10):1780-1788. PubMed ID: 31441962
[TBL] [Abstract][Full Text] [Related]
37. Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.
Munisvaradass R; Kumar S; Govindasamy C; Alnumair KS; Mok PL
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885562
[TBL] [Abstract][Full Text] [Related]
38. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Geyer MB; Brentjens RJ
Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
[TBL] [Abstract][Full Text] [Related]
39. New development in CAR-T cell therapy.
Wang Z; Wu Z; Liu Y; Han W
J Hematol Oncol; 2017 Feb; 10(1):53. PubMed ID: 28222796
[TBL] [Abstract][Full Text] [Related]
40. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
